MOXD1 and neuroblastoma: Stratifying patients from the Sequencing Quality Control (SEQC) cohort, previously reported by Zhang et al. (31), encompassing 498 individuals with neuroblastoma based on their MOXD1 expression revealed that tumors with the lowest (first quartile) MOXD1 expression had the worse overall survival (Fig. 1A).